Material Educativo

[Artigo] Hydroxychloroquine (All Populations Monograph)

Chloroquine monograph – Indications/Dosage
expand all | collapse all

Labeled

  • malaria
  • malaria prophylaxis
  • rheumatoid arthritis
  • systemic lupus erythematosus (SLE)

Off-Label, Recommended

  • coronavirus disease 2019 (COVID-19) †
  • lupus nephritis †
  • polymorphous light eruption †
  • severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection †

Per the manufacturer, this drug has been shown to be active against most strains of the following microorganisms either in vitro and/or in clinical infections:

Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, Plasmodium vivax.

NOTE: The safety and effectiveness in treating clinical infections due to organisms with in vitro data only have not
been established in adequate and well-controlled clinical trials.

This drug may also have activity against the following microorganisms:

severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

NOTE: Some organisms may not have been adequately studied during clinical trials; therefore, exclusion from this
list does not necessarily negate the drug’s activity against the organism.

Oral dosage

  • Adults

13 mg (10 mg base)/kg/dose [Max: 800 mg (620 mg base)/dose] PO, then 6.5 mg (5 mg base)/kg/dose
[Max: 400 mg (310 mg base)/dose] PO at 6, 24, and 48 hours after the initial dose.[41806] [64059] For P.
vivax or P. ovale, give in combination with primaquine phosphate or tafenoquine. Guidelines recommend
hydroxychloroquine for uncomplicated malaria in patients with chloroquine-sensitive P. falciparum or P.
vivax or in all patients with P. malariae, P. knowlesi, or P. ovale.[64059]

  • Children and Adolescents weighing 31 kg or more

13 mg (10 mg base)/kg/dose [Max: 800 mg (620 mg base)/dose] PO, then 6.5 mg (5 mg base)/kg/dose
[Max: 400 mg (310 mg base)/dose] PO at 6, 24, and 48 hours after the initial dose.[41806] [64059] For P.
vivax or P. ovale, give in combination with primaquine phosphate or tafenoquine (16 years and older).
Guidelines recommend hydroxychloroquine for uncomplicated malaria in patients with chloroquinesensitive P. falciparum or P. vivax or in all patients with P. malariae, P. knowlesi, or P. ovale.[64059]

Para continuar lendo, clique aqui. 

Para continuar navegando nos nossos Materiais educativos, clique aqui.

Like